One-Year Follow-up of Intracoronary Stem Cell Delivery on Left Ventricular Function Following ST-Elevation Myocardial Infarction

• Autores: Jay H. Traverse, Timothy D. Henry, Carl J. Pepine, James T. Willerson, Stephen G. Ellis
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 311, Nº. 3, 2014, págs. 301-302
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • The Timing In Myocardial Infarction Evaluation (TIME) trial1,2 assessed whether the timing of stem cell delivery affects the recovery of left ventricular (LV) function following myocardial infarction (MI). Patients with anterior ST-elevation MI (STEMI) who were reperfused with primary percutaneous coronary intervention and stenting and had at least moderate LV dysfunction (LV ejection fraction [LVEF] ≤45%) were randomized (2:1) to 150 million autologous bone marrow mononuclear cells (BMCs) or placebo with intracoronary delivery performed on day 3 (n = 67) or day 7 (n = 53). At 6 months, no benefit of cell therapy was observed compared with placebo following cell delivery at either time. We now report outcomes at 1 year. The collection of clinical end point and cardiac magnetic resonance imaging (MRI) data was prespecified but the analysis plan was post hoc.